Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Paula Tavares Guimarães"'
Autor:
Joyce Maria L. Maia, Angelo Bezerra de Souza Fêde, Monique Celeste Tavares, Vladmir Cláudio Cordeiro de Lima, Celso Silva e Souza Filho, Andrea Paiva Gadelha Guimarães, Solange Moraes Sanches, Caio Dabbous Liz, Bruno Cezar Mendonça Uchôa Júnior, Paula Tavares Guimarães, Lucas Vian, Mauro Daniel Spina Donadio, Adriana Regina Gonçalves Ribeiro, Marcelle Goldner Cesca, Ronaldo Pereira Souza, Augusto Saito, Iara Karoline Freire Lustosa, Samara Theodoro Pacheco, Luciana Beatriz Mendes Gomes, Noam Pondé, Marcelo Corassa, Fabrício de Souza Castro, M.F. Simões, Daniella Yumi Tsuji Honda
Publikováno v:
Cancer Research. 81:PS6-25
Background: Breast cancer (BC) accounts for 30% of female cancer, is the most commonly diagnosed cancer worldwide and the second most common cause of cancer-related deaths among females. The majority (79%) of breast cancers express the estrogen recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df7f94703f115c488e53f12922720d2f
https://doi.org/10.1158/1538-7445.sabcs20-ps6-25
https://doi.org/10.1158/1538-7445.sabcs20-ps6-25
Autor:
Rafael Lima Viana, M.F. Simões, Fernando Augusto Batista Campos, Vladmir Cláudio Cordeiro de Lima, Luciana de Moura Leite, Bruna Raphaeli Silva Mattos, Paula Tavares Guimarães, Noam Pondé, Debora Maciel Santana, Daniella Dias Silva Sá, F. Rocha, Sinara Figueiredo Silva, Erick Figueiredo Saldanha, Solange Moraes Sanches, Marcelle Goldner Cesca, Rafaela Pirolli, Camilla Albina Zanco Fogassa, Monique Celeste Tavares, Simone Klog Loose
Purpose: Recently, phase I studies with novel antibody drug conjugates targeting HER2 suggested benefit in HER2-low patients – defined as immunohistochemistry(IHC) +1 or +2 FISH/ISH non-amplified, with advanced breast cancer(BC). Data on the progno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d98fd26dd52572004e785fb728f0e6d0
https://doi.org/10.21203/rs.3.rs-420934/v1
https://doi.org/10.21203/rs.3.rs-420934/v1
Publikováno v:
Journal of Clinical Oncology. 39:50-50
50 Background: MTB is a valuable tool in complex cases, since they involve different medical fields aiming for a more comprehensive decision-making process. Our aims are to describe MTB decisions in complex LMCRC, to analyze decisions compliance and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9112b3f36adab0f80e77df2f0f037d4
https://doi.org/10.1200/jco.2020.39.28_suppl.50
https://doi.org/10.1200/jco.2020.39.28_suppl.50